Baseline characteristics of the 5135 female participants according to their mortality status at follow-up.

<p>Baseline characteristics of the 5135 female participants according to their mortality status at follow-up.</p

Cox proportional hazard models^a for the risk of dying associated with the use of current hormone treatment (versus non-current use) at baseline, stratified by estrogen receptor genotype.

a<p>This analysis was carried out on a sub-population of 4463 women for whom genotyping data was available.</p>b<p>Adjusted for age, education, living status, recruitment centre, incapacities, comorbidity, depressive symptoms and cognitive impairment.</p

Cause of death according to the use of hormone treatment at baseline.

a<p>Unadjusted chi-squared analysis for the difference in the frequency of deaths according to HT use.</p

Baseline characteristics of the 5135 female participants according to their use of hormone treatment.

<p>Baseline characteristics of the 5135 female participants according to their use of hormone treatment.</p

Cox proportional hazard models for the risk of all-cause deaths according to the use of hormone treatment at baseline.

a<p>Adjusted for age, education, recruitment centre, living situation, incapacities, comorbidity, depressive symptoms and cognitive impairment.</p>b<p>With reference to never users.</p>c<p>113 (89%) used transdermal estradiol treatment and 14 (11%) oral estradiol.</p>d<p>The 27 women who currently used other types of HT were not included in this analysis;</p